One of Dr. Morris’ patients encountered such a problem. The insurance plan refused to cover an infusion in the physician’s office and instead insisted that the patient go into the hospital in order to get the infusion covered. The patient had to find and pay for parking and then wait three hours for the procedure. The entire procedure cost three times as much in the hospital setting as it would have in Dr. Morris’ office. Dr. Morris and his patient complained to the insurance company, and the protocol changed.
Another common problem is obtaining prior authorization for drugs used in rheumatology that are also used in cancer treatment and transplantation, where they are covered by Medicare Part B. Having to obtain prior authorization is so common that a solution has been developed. Dan Fohrman, MD, of Bend Memorial Clinic in Bend, Ore., has worked as chair of a Regional Advisory Council for the ACR in conjunction with the CMS Physicians Regulatory Issues Team (PRIT) to propose a solution to this problem.
According to Dr. Fohrman’s solution, physicians are now instructed to write “Rheumatology Part D” directly on the prescription form for these particular drugs. PRIT agreed to inform insurers about this idea, but so far not all of the insurers are aware of the solution.
In March 2006, PRIT issued another directive, but the problem of disseminating the wording on the prescription form now seems to lie with the pharmacies. Neither CMS nor the insurers have told all pharmacists—particularly independent pharmacists—about PRIT’s directive. “The layers of communication are numerous, and there is not enough incentive for insurers to spread the word,” says Dr. Fohrman. “So far, there is no consequence if they don’t comply.”
Confusion about Authorization Rules
Many rheumatologists believe the need to obtain prior authorization on so many rheumatic drugs grew from a lack of knowledge about rheumatic disease on the part of those designing the individual benefit plans. Gerald Eisenberg, MD, director of rheumatology at the Illinois Bone and Joint Institute in Des Plaines, describes the prior authorization problem as having a “hassle factor,” but he is more confused about why so many commonly used drugs require prior authorization. He thinks the reason may be a lack of interest in or an emphasis on cost-effectiveness.